Vaidya Sane Ayurved Laboratories Quarterly Results for Trading Insights
In Sept 2023, Vaidya Sane Ayurved Laboratories (MADHAVBAUG) reported revenue ₹5,173 Cr and net profit ₹235 Cr — revenue -48.5% YoY. Also explore Vaidya Sane Ayurved Laboratori stock price data download to track price trends across different timeframes.
MADHAVBAUG Quarterly Results — Revenue, Profit & EPS Highlights
Vaidya Sane Ayurved Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Vaidya Sane Ayurved Laboratori screener.
- Revenue of ₹5,173 Cr in Sept 2023 (+11.5% vs Jun 2023, -48.5% vs Sept 2022)
- Net Profit of ₹235 Cr in Sept 2023 (-4.9% vs Jun 2023, -75.7% vs Sept 2022)
- EBITDA of ₹332 Cr in Sept 2023 (-33.6% vs Jun 2023)
- Operating Margin of 5.0% in Sept 2023 (-4.0pp vs Jun 2023)
- Earnings Per Share of ₹1.12 in Sept 2023 (-56.9% vs Jun 2023)
Vaidya Sane Ayurved Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
MADHAVBAUG quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2023 | Jun 2023 | Sept 2022 | QoQ | YoY |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 5,173 | 4,641 | 10,053 | 11.5% | -48.5% |
| Net Profit (₹ Cr) | 235 | 247 | 967 | - | - |
| EBITDA (₹ Cr) | 332 | 500 | 922 | - | - |
| EPS (₹) | 1.12 | 2.60 | 4.60 | - | - |
| Operating Margin (%) | 5.0% | 9.0% | 8.0% | - | - |
MADHAVBAUG Share Price Trend — 1-Year Movement Across Quarterly Results
Vaidya Sane Ayurved Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse Vaidya Sane Ayurved Laboratori financial data for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
MADHAVBAUG vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vaidya Sane Ayurved Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹457,721.13 Cr | 1912.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 169.3 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6857.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 242.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4822.7 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 419.0 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1472.3 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 214.3 |
|
Zydus Life Science
Mar 2026 |
₹115,505.60 Cr | 1147.9 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 90.7 |
All amounts in ₹ Crores